SUDDS Diagnostic Schedule

The Substance Use Disorder Diagnostic Schedule (SUDDS) is a structured clinical interview designed to systematically assess DSM-5 substance use disorder criteria across multiple substance categories through standardized questions, yielding definitive diagnostic classifications with specified severity levels. Unlike screening tools that identify risk, SUDDS provides diagnostic confirmation required for clinical decision-making, insurance authorization, and treatment planning. The tool directly maps to the 11 DSM-5 criteria organized into four domains: (1) Impaired Control includes using larger amounts or for longer than intended (Criterion 1), persistent desire or unsuccessful efforts to cut down (Criterion 2), great deal of time spent obtaining, using, or recovering (Criterion 3), and craving or strong urge to use (Criterion 4). (2) Social Impairment covers failure to fulfill major role obligations at work/school/home (Criterion 5), continued use despite persistent/recurrent social/interpersonal problems (Criterion 6), and giving up or reducing important activities (Criterion 7). (3) Risky Use assesses recurrent use in hazardous situations (Criterion 8) and continued use despite knowledge of persistent/recurrent physical/psychological problems (Criterion 9). (4) Pharmacological evaluates tolerance (Criterion 10) and withdrawal (Criterion 11). Each criterion is assessed through 2-4 specific questions with behavioral anchors. For example, Criterion 1 (larger amounts/longer) asks: "In the past 12 months, have you often used [substance] in larger amounts than you intended?" with follow-up probes: "Can you give me an example? How often did this happen?" Scoring follows DSM-5 thresholds: 0-1 criteria met = No diagnosis; 2-3 criteria = Mild SUD; 4-5 criteria = Moderate SUD; 6+ criteria = Severe SUD. A patient endorsing 7 criteria (larger amounts intended=yes, unsuccessful quit attempts=yes, time spent obtaining/using=yes, craving=yes, failed obligations=yes, hazardous use=yes, tolerance=yes) meets diagnosis of severe [substance] use disorder, indicating need for intensive treatment such as residential care or intensive outpatient programming. SUDDS administration takes 15-25 minutes per substance assessed and demonstrates excellent inter-rater reliability (kappa=0.85-0.92) when administered by trained clinicians.

SUDDS employs behaviorally-specific questions with concrete examples to standardize criterion assessment and minimize interpretation variability. Criterion 1 (Larger amounts/longer than intended): Questions: "Did you often use more [substance] than you planned?" "Did your use sessions often last longer than you meant them to?" Example endorsement: Patient reports planning to have 2-3 drinks at social events but consistently consuming 7-10 drinks; or intending to use cannabis once before bed but continuing to smoke for 3-4 hours. Criterion 2 (Unsuccessful efforts to cut down): "Have you tried to cut down or stop using [substance]?" "How many times?" "What happened?" Example: Patient reports 5 separate attempts to quit cocaine in past year, each lasting 2-14 days before relapse despite sincere intention to stop. Criterion 3 (Time spent): "How much time do you spend getting [substance], using it, or recovering from its effects?" "Does this interfere with other activities?" Example: Opioid user spends 3-4 hours daily traveling to obtain drugs, using, and experiencing drowsiness afterward, limiting ability to work or care for family. Criterion 4 (Craving): "Have you had strong urges or cravings to use [substance]?" "How often?" "How intense?" Example: Patient experiences daily intense urges to use methamphetamine, describing them as 8-9/10 intensity, often triggered by specific locations or stress. Criterion 5 (Role obligations): "Has your [substance] use caused you to miss work or school?" "Has it affected your performance at work/school?" "Has it interfered with taking care of your home or family?" Example: Alcohol user calls in sick 6 times in past year due to hangovers, receives performance warnings, and neglects household responsibilities on weekends due to heavy drinking. Criterion 6 (Social/interpersonal problems): "Has your [substance] use caused arguments or problems with family or friends?" "Do you continue using even though it causes these problems?" Example: Cannabis use leads to repeated conflicts with spouse who threatens divorce unless patient quits, yet use continues despite marital distress. Criterion 7 (Activities given up): "Have you given up or reduced important activities because of [substance] use?" "What activities?" Example: Previously avid runner who competed in marathons stops training completely due to cocaine use; former volunteer who discontinues community service to spend time obtaining/using drugs. Criterion 8 (Hazardous use): "Have you used [substance] in situations where it was physically dangerous?" "Such as driving, operating machinery, or swimming?" Example: Patient drives while intoxicated 10+ times in past year; uses benzodiazepines before operating heavy equipment; uses stimulants while alone hiking in remote areas. Criterion 9 (Physical/psychological problems): "Do you have any physical health problems that are caused or worsened by [substance]?" "Mental health problems?" "Do you keep using despite knowing this?" Example: Patient with alcohol-induced gastritis and elevated liver enzymes continues drinking despite physician warnings; cocaine user experiencing panic attacks and chest pain continues use despite health fears. Criterion 10 (Tolerance): "Do you need to use more [substance] to get the same effect?" "Or does the same amount have less effect than before?" Example: Heroin user reports needing to increase from 0.2g to 0.8g daily to achieve desired effect; alcohol user who formerly felt intoxicated after 4 drinks now requires 10-12 drinks. Criterion 11 (Withdrawal): "When you stop or reduce [substance], do you experience withdrawal symptoms?" Follows with substance-specific symptom lists (e.g., alcohol withdrawal: tremors, sweating, anxiety, insomnia, nausea, hallucinations; opioid withdrawal: muscle aches, insomnia, dilated pupils, gastrointestinal distress). Example: Benzodiazepine user experiences severe anxiety, tremors, and insomnia when attempting to stop, requiring resumption of use for symptom relief. Someone endorsing Criteria 1, 2, 3, 4, 5, 8, 10 (7 total) receives severe cannabis use disorder diagnosis, warranting intensive treatment referral.

SUDDS employs substance-specific modules administered separately for each substance category, recognizing that use patterns, consequences, and diagnostic criteria manifestation vary across drug classes. Standard SUDDS assesses 10 primary substance categories: alcohol, cannabis, cocaine/crack, amphetamines/methamphetamine, opioids (prescription and heroin assessed separately or combined), sedatives/hypnotics, hallucinogens, inhalants, phencyclidine (PCP), and other substances. Each substance receives independent DSM-5 diagnostic assessment because a person may meet criteria for multiple distinct substance use disorders simultaneously. Administration strategy: Screening questions first identify substances used in past 12 months. For example: "In the past year, have you used: alcohol, cannabis, cocaine, stimulants, opioids, sedatives, hallucinogens?" For each substance endorsed, the full 11-criterion assessment is conducted. Someone reporting past-year alcohol, cannabis, and cocaine use would complete three separate SUDDS modules, potentially yielding diagnoses of moderate alcohol use disorder (4 criteria), severe cannabis use disorder (7 criteria), and mild cocaine use disorder (3 criteria). This specifies that cannabis represents the most severe substance problem requiring primary treatment focus, while alcohol and cocaine need monitoring and brief intervention. Polysubstance diagnostic considerations: DSM-5 eliminated the separate "polysubstance dependence" diagnosis, requiring instead that each substance meeting criteria receive distinct diagnosis. However, polysubstance use creates unique assessment challenges: Overlapping criteria: Someone using both alcohol and benzodiazepines might attribute withdrawal symptoms to either substance, requiring detailed clinical interview to distinguish. Interactive effects: Concurrent use of multiple substances (e.g., cocaine plus alcohol creating cocaethylene) may produce combined impairment exceeding single substances, affecting hazardous use and role obligation criteria. Primary substance identification: Treatment planning requires identifying the substance causing greatest harm. SUDDS clinicians consider: which substance has highest severity rating (most criteria met), which causes most functional impairment (role obligations, activities given up), which presents greatest medical risk (injection heroin versus oral cannabis), and which substance the patient prioritizes addressing. Example polysubstance assessment: A 28-year-old patient reports past-year use of alcohol, cannabis, cocaine, and prescription opioids. SUDDS assessment reveals: Alcohol: 5 criteria met (larger amounts, time spent, cravings, role obligations, tolerance) = Moderate alcohol use disorder. Cannabis: 3 criteria met (larger amounts, cravings, activities given up) = Mild cannabis use disorder. Cocaine: 8 criteria met (larger amounts, unsuccessful quit attempts, time spent, cravings, role obligations, interpersonal problems, hazardous use, tolerance) = Severe cocaine use disorder. Opioids: 2 criteria met (larger amounts, cravings) = No diagnosis (sub-threshold). Diagnostic summary: Severe cocaine use disorder, moderate alcohol use disorder, mild cannabis use disorder. Treatment plan prioritizes cocaine as primary focus given severe classification, incorporates alcohol reduction strategies given moderate severity, and monitors cannabis use. Opioid use, though present, doesn't meet diagnostic threshold but warrants monitoring given polysubstance pattern. Sequential versus simultaneous use: SUDDS distinguishes between simultaneous polysubstance use (using multiple substances in same session, e.g., speedball combining heroin and cocaine) versus sequential use (using different substances on different occasions). Simultaneous use typically indicates more severe disorder and worse prognosis. Substance-specific withdrawal and tolerance: Criterion 11 (withdrawal) and Criterion 10 (tolerance) are assessed using substance-specific symptom profiles: Alcohol withdrawal includes tremors, sweating, insomnia, nausea, hallucinations, seizures. Opioid withdrawal includes muscle aches, lacrimation, rhinorrhea, sweating, diarrhea, dilated pupils. Stimulant withdrawal includes fatigue, increased appetite, psychomotor retardation, depression. Cannabis withdrawal includes irritability, insomnia, decreased appetite, restlessness, depressed mood. Tolerance varies dramatically across substances—some daily cannabis users never develop significant tolerance while opioid users typically develop substantial tolerance within weeks. Documentation: SUDDS generates comprehensive diagnostic report listing all substance use disorders met with severity levels, criterion-by-criterion scoring, and treatment recommendations based on diagnostic profile.

The DSM-5's dimensional severity classification system represents a fundamental shift from prior categorical diagnoses (abuse versus dependence), with SUDDS operationalizing severity through criterion counting that directly informs treatment intensity matching: Mild SUD (2-3 criteria): Represents early-stage problematic use with limited functional impairment. Commonly endorsed criteria at mild level include Criterion 1 (larger amounts than intended), Criterion 2 (unsuccessful quit attempts), Criterion 4 (cravings), and Criterion 10 (tolerance). For example, a college student who meets 3 criteria for alcohol use disorder (drinks more than planned at parties, has tried to cut back twice without success, notices needing 6 drinks to feel effects that previously required 3 drinks) shows mild severity. Treatment implications: Brief intervention (5-20 minutes motivational interviewing-based counseling), outpatient individual counseling (1 session weekly for 8-12 weeks), educational groups, self-help meetings (AA, NA), or monitored natural recovery may suffice. Many mild SUD cases respond to minimal intervention, with 40-50% achieving sustained improvement with brief intervention alone. Moderate SUD (4-5 criteria): Indicates established problematic use with notable functional impairment but not yet extreme severity. Typical pattern includes criteria from multiple domains: impaired control (larger amounts, quit attempts, craving), some social impairment (occasional role failures, relationship conflicts), and possibly pharmacological criteria (tolerance, mild withdrawal). Example: A 35-year-old meeting 5 criteria for opioid use disorder (taking more pills than prescribed, multiple failed attempts to stop, 2-3 hours daily managing prescriptions and use, cravings, job performance decline, tolerance) shows moderate severity. Treatment implications: Intensive outpatient program (IOP: 9-12 hours weekly for 8-12 weeks), standard outpatient counseling (2-3 sessions weekly), medication-assisted treatment for opioid/alcohol use disorder (buprenorphine, naltrexone, disulfiram, acamprosate), active recovery support (intensive 12-step involvement, recovery coaching), and treatment of co-occurring disorders. Moderate SUD typically requires 3-6 months of active treatment with 6-12 months continuing care. Severe SUD (6-11 criteria): Represents extensive problematic use with substantial impairment across multiple life domains. Patients typically endorse criteria from all four domains including serious social consequences (job loss, family breakdown), dangerous use patterns, and significant pharmacological dependence. Example: A patient meeting 9 criteria for methamphetamine use disorder (larger amounts, quit attempts, extensive time spent obtaining/using, intense cravings, job loss, family estrangement, continued use despite psychotic symptoms, tolerance, withdrawal) demonstrates severe disorder. Treatment implications: Residential treatment (24/7 care for 30-90 days), partial hospitalization program (PHP: 20+ hours weekly), medically-supervised withdrawal management when indicated, long-term medication-assisted treatment, intensive case management, integrated treatment for psychiatric/medical comorbidities, extended continuing care (1-2 years), and recovery housing (sober living, halfway house). Severe SUD requires 6-12 months intensive treatment with 1-2 years step-down care for optimal outcomes. Treatment matching research: Studies demonstrate that severity-matched treatment produces better outcomes than mismatched care. Severe SUD patients in outpatient-only treatment show 60-70% dropout and relapse rates versus 40-50% with residential treatment. Conversely, mild SUD patients in residential treatment show comparable outcomes to those receiving brief intervention but at 10-20x higher cost, representing inappropriate resource utilization. Dynamic severity assessment: Severity can change rapidly with intervention or progression. Someone entering treatment with severe SUD (8 criteria) might show moderate severity (4 criteria) at 3-month follow-up if successfully engaged in treatment—no longer experiencing cravings (Criterion 4 resolved), meeting role obligations (Criterion 5 resolved), not using hazardously (Criterion 8 resolved), reduced tolerance (Criterion 10 resolved)—reflecting clinical improvement warranting step-down to less intensive care. Conversely, someone with mild SUD who declines intervention may progress to moderate or severe within 6-12 months as consequences accumulate. Severity modifiers: Beyond criterion count, SUDDS documentation includes severity modifiers affecting prognosis and treatment planning: Early remission (3-12 months abstinent or sub-threshold criteria), sustained remission (12+ months), in controlled environment (incarcerated, residential), and on maintenance therapy (buprenorphine, methadone). A patient with history of severe opioid use disorder currently meeting 0 criteria while on buprenorphine for 14 months receives diagnosis: Opioid use disorder, severe, in sustained remission, on maintenance therapy. This specifies continued MAT is medically necessary despite current remission.

SUDDS demonstrates strong psychometric properties as a diagnostic instrument, though practical limitations affect clinical implementation: Reliability evidence: Inter-rater reliability: When administered by trained clinicians, SUDDS shows excellent agreement on diagnostic presence/absence (kappa=0.85-0.92 across substances) and good agreement on severity level (kappa=0.78-0.85). This indicates that different clinicians interviewing the same patient reach highly consistent diagnostic conclusions. Reliability is highest for objective criteria with clear behavioral anchors (Criterion 5: role obligations, Criterion 8: hazardous use) and somewhat lower for subjective internal states (Criterion 4: craving, Criterion 9: continued use despite problems). Test-retest reliability: Patients re-interviewed within 2-4 weeks show consistent diagnostic classifications (kappa=0.82-0.88), though symptom-level responses vary more (kappa=0.65-0.75), partly reflecting genuine symptom fluctuation over time. Internal consistency: The 11 DSM-5 criteria show moderate inter-correlation (alpha=0.75-0.82), supporting the unidimensional construct of substance use disorder while allowing for heterogeneous clinical presentations. Validity evidence: Concurrent validity: SUDDS diagnoses correlate strongly with clinician diagnoses using unstructured interviews (kappa=0.78-0.85) and with other structured instruments like SCID (Structured Clinical Interview for DSM, kappa=0.82-0.91). Convergent validity: SUDDS severity levels correlate with substance use frequency (r=0.62-0.75), functional impairment measures (r=0.58-0.70), and treatment need assessments (r=0.66-0.78). Someone diagnosed with severe SUD typically uses substances more frequently, experiences greater impairment, and requires more intensive treatment than someone with mild SUD. Predictive validity: Baseline SUDDS severity predicts treatment outcomes: severe SUD patients show lower abstinence rates at 12-month follow-up (30-40%) versus moderate (50-60%) and mild (65-75%) patients in naturalistic treatment studies. Higher criterion counts predict treatment retention, with each additional criterion reducing completion likelihood by approximately 8-10%. Discriminant validity: SUDDS distinguishes substance use disorder from other psychiatric conditions—correlation with depression/anxiety measures is modest (r=0.30-0.45), confirming specificity while acknowledging comorbidity. Clinical utility: SUDDS provides clear diagnostic thresholds (2+ criteria) with high sensitivity (85-92%) and specificity (80-88%) compared to expert clinical diagnoses as gold standard. Limitations and biases: (1) Self-report reliance: Like all interview-based diagnostics, SUDDS depends on honest, accurate patient reporting. Patients may minimize symptoms due to shame, legal concerns, or poor insight (anosognosia). Validation studies comparing SUDDS to collateral informant reports and biological testing reveal underreporting in 25-40% of cases, particularly for illegal substances and criminal behaviors. Mitigation: Establish rapport and confidentiality, use Timeline Follow-Back methods for detailed use assessment, corroborate with urinalysis and collateral sources when possible, train interviewers to recognize minimization patterns. (2) Threshold effects: DSM-5's 2-criterion diagnostic threshold creates cliff effects where someone endorsing 1 criterion (no diagnosis) may have significant problems warranting intervention, while someone endorsing 2 criteria (mild SUD) receives formal diagnosis. Some clinicians use 1-criterion cases as "sub-threshold SUD" warranting monitoring. (3) Criterion weighting: DSM-5 counts all criteria equally, but some (e.g., Criterion 11: withdrawal indicating physiological dependence) may carry greater clinical significance than others (e.g., Criterion 1: larger amounts) for certain substances and treatment decisions. SUDDS doesn't weight criteria differentially. (4) Time frame: The 12-month assessment window may miss acute recent changes. Someone who used heavily for 11 months but has been abstinent for past month might still meet multiple criteria, yet their current clinical status (early remission) differs dramatically from someone meeting same criteria through continuous active use. Mitigation: Separately assess past month and past year, apply specifiers (early remission, sustained remission). (5) Training requirements: Valid SUDDS administration requires clinician training in structured interviewing, DSM-5 criteria, and substance use terminology. Untrained administrators show substantially lower inter-rater reliability (kappa=0.55-0.65). Programs should provide 8-12 hours initial training with ongoing reliability checks. (6) Time burden: Comprehensive SUDDS administration takes 15-25 minutes per substance, creating barriers in high-volume settings. Brief screening tools (ASSIST, DAST) are more practical for initial case finding, reserving SUDDS for diagnostic confirmation in positive screens. (7) Cultural factors: SUDDS validation occurred primarily in Western populations; criterion manifestation may differ across cultures. For example, "failure to fulfill major role obligations" (Criterion 5) interpretations vary across cultural contexts with different work patterns and family structures. Criterion assessment should consider cultural norms while maintaining diagnostic standardization. Despite limitations, SUDDS represents one of the most reliable and valid tools for operationalizing DSM-5 substance use disorder diagnoses, with strong psychometric support for clinical and research applications when administered by trained professionals.